Our findings provide novel mechanistic insight into tumor aggressiveness that is associated with MT-mediated upregulation of FGF19/FGFR4 signaling axis, suggesting that inactivating this molecular node may help actualize the promise of MT supplements in cancers. This evidence concerns the gene FGF19 and cancer.